Skip to main content

Paragraph IV Disputes Master Symposium

American Conference Institute


Date: October 2, 2017 - October 3, 2017

Time: 5:00AM - 1:00PM

Location: Chicago, Illinois


  • Ethics Lab for Paragraph IV Practice: Identifying and Avoiding Ethics Pitfalls in Hatch-Waxman Litigation
  • Novartis v. Noven – A Study in Obvious Contrasts: Dilemmas Associated with Different Standards of Review

Event Details

ACI’s industry-leading Paragraph IV Disputes Master Symposium enters its fifth iteration this fall. This event will pick up where ACI Paragraph IV conference left off to bring you up-to-the minute information on the latest developments affecting ANDA litigation.

Preeminent patent litigators representing brand name and generic drug makers, leading in-house counsel, and esteemed jurists will provide insights on such matters as:

  • The impact of TC Heartland on jurisdiction and venue
  • The legal and business repercussions of Helsinn
  • Amgen v. Sandoz from an ANDA litigator’s point of view
  • The FDA Final MMA Rule
  • Novartis v. Noven and differing standards of review
  • Secondary considerations in obviousness reviews
  • Alternative forums: PTAB and ITC
  • Oil States vs. Greene’s Energy Group and the constitutionality of IPR proceedings
  • Exceptional case findings
  • Reverse payment settlements
  • Patent lawsuit risk assessment and other IP due diligence essentials


Professional Cropped Conlin Dave Mintz

David G. Conlin


David G. Conlin helps plan, establish, maintain, and enforce clients’ intellectual property portfolios for Mintz. He assists clients with protecting their freedom to operate amid improperly alleged IP infringement, and his teams have driven the issuance of over 3,700 patents.
Kathleen B. Carr is a Mintz attorney with more than 20 years of experience as lead counsel on federal and state court cases. She has led trial teams on Hatch-Waxman pharmaceutical patent litigation, and she's registered to practice before the US Patent and Trademark Office.